Genocea Biosciences $GNCA announced encouraging top-line results from an ongoing Phase 2b clinical trial evaluating a lead product candidate GEN-003 for the treatment of genital herpes. The study met its primary endpoints, showing a statistically valid reduction of 40% from baseline (60 ug per protein/50 ug of Matrix-M2 dose) in the rate of viral shedding compared to placebo (p=0.05). The results were consistent with an earlier Phase 2 study.

FDA asks Alcobra to hold Study on MDX Program; Shares Hammered- Alcobra $ADHD nosedived on Thursday amid increased volume trading as a reaction to the news that it got a verbal notice from the FDA asking it to put on hold its Metadoxine Extended Release (MDX) program from clinical trial due to adverse neurological findings in a preclinical study. The action suspends enrolment and dosing in its Phase 3 MEASURE study in adults with attention deficit hyperactivity disorder despite the absence of questionable safety data. There have also been no safety issues in earlier MDX clinical trials. The company intends to work closely with the agency to remove the clinical hold.

NeuroDerm Prolongs Timeline to submit applications for Parkinson’s Candidate ND0612-NeuroDerm $NDRM will take more time to activate clinical trials sites in specific countries that are participating in its long-term safety study (trial 012, the “Beyond” trial), evaluating ND0612, its continuous, dermatologically delivered levodopa/carbidopa (LD/CD) liquid formulation for treatment of Parkinson’s disease. The drug-maker expects to submit marketing applications in H1 2018. Earlier, it was supposed to submit at the end of 2017.

Marinus Pharma’s Clinical Results Fail to Inspire Investors-Marinus Pharmaceutical’s $MRNS shares plummeted on Thursday amid high-volume trading in response to its announcement of topline results related to a small exploratory open-label clinical trial of GABA modulator ganaxolone in females with PCDH19 pediatric epilepsy, an orphan drug designation by the U.S. regulator. The study assessed ganaxolone as an adjunctive treatment, administered as oral liquid suspension or capsule for 26 weeks after establishing baseline seizure frequency up to 12 weeks.

Sunshine Heart to make a Strategic Shift; Focus in AquadexFlow- Sunshine Heart $SSH announced on Thursday that it will be making a strategic change in the near-term by focusing its resources on its newly acquired Aquadex FlexFlow System. The Aquadex system is indicated for temporary (up to 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (more than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Novo Nordisk to Slash 1000 jobs- As a part of its cost cutting measures, Novo Nordisk $NVO announced that it will slash 1000 positions from its international workforce of 42,300. Half of the job cuts will be in Denmark. The decision will be communicated through individual notices in the next two months. The cuts will effect positions in the R&D department, headquarter staff and the global commercial organization.

The Japanese Ministry of Health, Labor, amd Welfare approved CSL Behring’s IDELVION. The drug prevents bleeding tendency is patients with haemophilia B (factor IX deficiency). The special approval includes regular prophylaxis, on demand control of bleeding episodes and the perioperative management of bleeding. It maintains factor IX activity at an average of 20%, when administered prophylactically every seven days and at an average of 12% when administered every 14 days. Tickers related Haemophilia B: $QURE, $ONCE, $NVO, $BAX, $BIIB, $DMTX, $SGMO

No patents to report.

Tesaro $TSRO and China Shanghai-based Zai Lab Co. announced a collaboration for the development and commercialization  of niraparib, an once-a-daily PARP inhibitor, in China and to advance two immune-oncology programs outside China. According to the terms of the agreements, the Chinese company will receive an exclusive license to develop niraparib for the local market, which also gives TESARO an option to commercialize the treatment in Greater China. Under the terms of the partnership, Zai Lab receives an exclusive license to development niraparib in country, which includes an option for TESARO to participate in the commercialization of niraparib in greater China.

Arrowhead Pharmaceuticals $ARWR signed two agreements with Amgen $AMGN for RNA interference (RNAi) therapies for cardiovascular disease (CVD) based on its proprietary subcutaneous RNAi delivery platform. Shares edged higher on Thursday.

Rennova Health, Inc. $RNVA inked a definitive agreement to acquire Pharmacogenetic Laboratory, Genomas. According to the terms of the deal, shareholders of Pharmacogenetic Laboratory will get $1.75mn in newly created series F convertible preference shares. $RNVA will assume about $800,000 of existing debt. Gualberto Ruano will continue to serve as president, and medical director of Genomas, which will now be a subsidiary of the company.

Medigene AG $MDGEF and bluebird bio $BLUE entered in a strategic R&D collaboration and license agreement for T cell receptor (TCR) immunotherapies against four targets. Under the terms of the deal, Medigine will receive an upfront fee of $15mn and up to $1bn in milestones for the four candidates across several indications, R&D funding and up to double digit tiered royalties on net sales.

South Korea’s Hanmi Pharmaceutical $HANPF signed an exclusive development and license agreement with Roche’s Genentech $RHHBY to develop and commercialize Hanmi’s pan-RAF inhibitor, Phase 1 clinical trial, HM95573. According to the terms of the agreement, Hanmi will receive an upfront fee of $80mn, $830mn in milestones, and tiered double-digit royalties on net sales.

Catabasis Pharmaceuticals $CATB soared on Thursday amid increased volume trading in response to its announcement of joint research collaboration with Sarepta Therapeutics $SRPT to assess a combination drug approach for the treatment of Duchenne muscular dystrophy (DMD). Sarepta will contribute its know-how on exon skipping and Catabasis its expertise in oral NF-kB inhibition, especially edasalonexent (CAT-1004).

Actinium Pharmaceuticals $ATNM announced its secondary offering of 8mn shares of common stock at $1.25. The underwriters will be eligible to purchase an additional 1.2mn shares. Shares, however, nosedived in reaction to the news. The net-proceeds from the offering are expected at $9mn and the closing date is October 4. The stock closed at $1.70 on Wednesday.

Fulgent Genetics announced the pricing of its $38 million IPO. The company offered 4.2 million shares at $9 per share, which is at the low end of its IPO range of $9 per share to $11 per share. The company had originally planned to raise 4.6 million shares at a range of $12 per share to $14 per share. Fulgent Genetics will list its shares on the NASDAQ under the ticker symbol FLGT. The company is provider of genetic testing for more than

Cantel Medical $CMN announced fiscal fourth quarter results on Thursday. It posted revenues of $179mn, an increase of 18.3%. Operating income was $25.8mn, up 16.7%. Net income rose 22.6% to $16.3mn. EPS for the quarter came at $0.39, an increase of 21.9%. Non GAAP EPS rose 23.1% to $0.48. The company did not provide guidance. Results for the FY2016: Revenues: $664.8M (+17.7%); Operating Income: $97.3M (+20.4%); Net Income: $60M (+25.0%); EPS: $1.44 (+25.2%); Non-GAAP EPS: $1.75 (+21.5%); Quick Assets: $28.4M (-10.4%).

Company (Ticker) Brokerage Action Recommendation Price Target My Price Target
Abeona Therapeutics (ABEO) Maxim Group Price Target Raised Buy From $8 to $14 N/A
Alcobra (ADHD) Oppenheimer Holdings Downgrade From Outperform to Market Perform N/A N/A
Alcobra (ADHD) Piper Jaffray Cos. Downgrade From Overweight to Neutral N/A N/A
Alcobra (ADHD) Cantor Fitzgerald Downgrade/Price Target Cut From Buy to Hold From $16 to $2 N/A
Aerie Pharmaceuticals (AERI) Brean Capital Price Target Set Buy

$48

N/A
Akebia Therapeutics (AKBA) Brean Capital Initiation Buy

$18

N/A
Alere (ALR) Canaccord Genuity Price Target Cut Buy From $56 to $53 N/A
Arrowhead Research Pharmaceuticals (ARWR) Cantor Fitzgerald Reiterate Buy N/A

$14.50

Arrowhead Research Pharmaceuticals (ARWR) Chardan Capital Price Target Set Buy

$10

$14.50

Anavex Life Sciences (AVXL) FBR & Co. Price Target Set Buy

$10

N/A
Aytu Biosciences (AYTU) HC Wainwright Reiterate Buy

$9

N/A
bluebird bio (BLUE) Maxim Group Price Target Raised Buy From $85 to $100 N/A
Catabasis Pharmaceuticals (CATB) Wedbush Reiterate Outperform

$17

N/A
Celgene (CELG) Citigroup Price Target Raised Buy From $124 to $127

$140

Endo International Plc (ENDP) Northland Securities Upgrade From Market Perform to Underperform N/A N/A
Endo International Plc (ENDP) Mizuho Downgrade From Outperform to Sell N/A N/A
Galectin Therapeutics (GALT) HC Wainwright Downgrade/Price Target Cut From Buy to Neutral From $8 to $1.50 N/A
Genocea Biosciences (GNCA) Piper Jaffray Cos. Price Target Cut Overweight From $12 to $9

$10.30

Genocea Biosciences (GNCA) Needham & Company Reiterate Buy

$15

$10.30

Horizon Pharma (HZNP) Mizuho Reiterate Buy N/A N/A
Idexx Laboratories Bank of America Initiation Neutral N/A N/A
Incyte (INCY) Raymond James Financial Upgrade From Market Perform to Outperform

$115

N/A
Intra-Cellular Therapies (ITCI) Royal Bank of Canada Price Target Cut Outperform From $74 to $49 N/A
Intra-Cellular Therapies (ITCI) JMP Securities Downgrade From Outperform to Market Perform N/A N/A
Intra-Cellular Therapies (ITCI) SunTrust Banks Downgrade From Buy to Neutral N/A N/A
Mallinckrodt (MNK) Mizuho Price Target Cut Buy From $91 to $89 N/A
Teva Pharmaceutical Industries (TEVA) OTR Global Initiation Positive N/A N/A
Vertex Pharmaceuticals (VRTX) Stifel Nicoualus Price Target Set Buy

$109

N/A
Vertex Pharmaceuticals (VRTX) Maxim Group Reiterate Hold N/A N/A
Acceleron Pharma (XLRN) Citigroup Initiation Neutral

$40

N/A

Opko Health (OPK)- Dr. Phillip Frost, CEO & Chairman, bought 3,600 shares at $10.67. The total value of the transaction was $38,418. Dr. Frost now owns 160,166,743 shares of OPK.

Achaogen (AKAO)- Blake Wise, COO, sold 3,632 shares at $4.30. The total value of the transaction was $15,620. Wise still owns 45,118 shares of AKAO. Zeryn Sarpangal, VP, HR and Corporate Affairs, sold 1,069 shares at $4.30. The total value of the transaction was $4,597. Sarpangal still owns 17,742 shares of AKAO.

BioMarin Pharmaceuticals (BMRN)- Jeffrey R. Ajer, EVP, Chief Commercial Officer, sold 18,467 shares at $95.61. The total value of the transaction was $1.76 million. Ajer still owns 41,342 shares of BMRN.

Synergy Pharmaceuticals (SGYP)- Paulson & Co. Inc., a 10% owner, sold 54,300 shares in two separate transactions. Paulson & Co. sold 33,600 shares at $5.75; and 20,700 shares at $5.60. Paulson & Co. still owns 24,228,655 shares of SGYP.

Atara Biotherapeutics (ATRA)- Isaac E. Ciechanover, CEO, sold 12,000 shares in three separate transactions. Ciechanover sold 7,200 shares at $20.50; 300 shares at $21.82; and 4,500 shares $21.40. Ciechanover still owns 406,878 shares of ATRA.

Kite Pharma (KITE)- Cynthia M. Butitta, COO, sold 10,000 shares at $54.13. The total value of the transaction was $541,300. Butitta still owns 95,477 shares of KITE.

No management changes and additions to report.

NYSE- Valeant Pharmaceuticals International (VRX) shares were among the major losers on the NYSE. The stock closed 5.19% lower. Teva Pharmaceutical Industries (TEVA) ended the day 4.91% lower.

NASDAQ- Catabasis Pharmaceuticals (CATB) was one of the major gainers on the NASDAQ. The stock closed 39.51% higher. Merus (MRUS) ended the day 22.90% higher. Aegerion Pharmaceuticals (AEGR) shares ended the day 22.89% higher. Intra-Cellular Therapies (ITCI) shares were among the major losers on the NASDAQ. The stock closed 63.59% lower. Alcobra )(ADHD) ended the day 45.67% lower. Marinus Pharmaceuticals (MRNS) ended the day 26.74% lower.

NYSEMKT- Actinium Pharmaceuticals (ATNM) shares were among the major movers on the NYSEMKT. The stock closed 21.30% lower.

OTC- Amarantus Bioscience Holdings (AMBS) shares were among the major movers on the OTC market. The stock closed 3.85% higher.

Company (Ticker) Short Interest as a % of Float % Change Days to Cover
Abbott Laboratories (ABT)

4.6%

4.9%

8

AbbVie (ABBV)

2.3%

-3.2%

6

Abeona Therapeutics (ABEO)

4.9%

14.4%

5

ABIOMED (ABMD)

4.5%

-11.9%

6

ACADIA Pharmaceuticals (ACAD)

15.2%

-3.1%

11

Acceleron Pharma (XLRN)

8.4%

2.8%

9

AcelRx Pharmaceuticals (ACRX)

13.7%

-1.1%

7

Achaogen (AKAO)

2.1%

1.2%

2

Achillion Pharmaceuticals (ACHN)

11.5%

-2.5%

8

Aclaris Therapeutics (ACRS)

6.5%

3.8%

6